REG - Malin Corp PLC - Poseida announces positive clinical data

MalinAnnouncement

05/09/2018 14:50

RNS Number : 8938Z
Malin Corporation PLC
05 September 2018
 


 
Malin Corporation plc
 
("Malin" or "the Company")
 
Poseida Therapeutics announces positive clinical data with its stem cell memory CAR-T product in patients with multiple myeloma
 
Dublin-Ireland, 5 September 2018: Malin Corporation plc. (ISE:MLC, "Malin"), a company investing in high-growth opportunities in the global healthcare sector, is pleased to note an encouraging update from an ongoing clinical study by one of its Investee companies, Poseida Therapeutics ("Poseida"). Malin owns an approximately 33% stake in Poseida.
 
Data from the first eleven relapsed/refractory multiple myeloma patients treated with Poseida's P-BCMA-101 stem cell memory CAR-T product show that all eleven patients remain on study with seven of ten patients evaluable by International Myeloma Working Group (IMWG) criteria achieving at least a partial response.
 
P-BCMA-101 is also demonstrating exceptional safety, with only one instance of suspected cytokine release syndrome (9%) that was minimal and short-lived. No patients demonstrated neurotoxicity and no patients required admission to an intensive care unit or treatment with tociluzimab or steroids, interventions typically required during episodes of CRS elicited by other CAR-T therapies. Enrollment continues in the higher dose cohorts.
 
Poseida's P-BCMA-101 is a CAR-T immunotherapy designed to supercharge a patient's own T cells to safely and effectively eliminate tumour cells via B cell maturation antigen (BCMA), which is expressed on essentially all multiple myeloma cells. P-BCMA-101 modifies a patient's T cells using its proprietary non-viral gene delivery system, piggyBac™, which provides several features to increase efficacy while minimising toxicity.
 
"The latest data results show that P-BCMA-101 induces deep responses in a heavily pretreated population with relapsed/refractory multiple myeloma, with some patients reaching VGPR and even stringent CR at early efficacy assessments" said Eric Ostertag, M.D., Ph.D., chief executive officer of Poseida Therapeutics.
 
Dr. Adrian Howd, Chief Executive Officer at Malin, said: "This is an excellent outcome for Poseida, one of our core investments, offering further positive clinical validation of this promising approach to cancer treatment. Malin owns approximately one third of Poseida and the company's progress in 2018, combined with increasing sector interest in the CAR-T space in general, strengthens our confidence in Poseida as a potential source of continued significant value creation for our shareholders."
 
A copy of Poseida Therapeutics' press release is available here:
 
 http://www.rns-pdf.londonstockexchange.com/rns/8938Z_1-2018-9-5.pdf
 
ENDS
 
 
 
For further information, please contact:
 
Malin
Adrian Howd, CEO
Tel: +353 (0)19015700
 
Consilium Strategic Communications (Financial PR)
Mary-Jane Elliott / Jonathan Birt
Tel: +44 (0)20 3709 5700
malin@consilium-comms.com 
 
Davy Corporate Finance (ESM Adviser)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
 
About Malin Corporation plc
Malin (ISE:MLC) is a company investing in high-growth opportunities in the global healthcare sector. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science, with a proven, sustainable business model. Formed in 2015, Malin works with its diverse portfolio of investee companies, providing strategic and financial support to enable them to reach their value potential. Malin, with a strong leadership team and Board, is headquartered and domiciled in Ireland and listed on Euronext Dublin, with offices in London and a global investment focus. For more information visit www.malinplc.com 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLLFSVAEIEIIT